Table 1. Enrolled patients in first-in-human phase 1 clinical trial of LUM015.

Imaging time was measured as the number of hours elapsed between LUM015 injection and imaging of the resected tissues with the LUM device. Histological descriptors are based on clinical surgical pathology reports. ER, estrogen receptor; PR, progesterone receptor; RT, radiation therapy.

PatientLUM015 dose
(mg/kg)
Imaging time
(hours)
Tumor typeTumor
grade
Tumor volume
(cm3)
Neoadjuvant
therapy
Tumor site
10.530.1Well-differentiated liposarcomaLow10.5 × 8.5 × 6.2NoneRetroperitoneal
20.528.5UPSHigh13.5 × 8.3 × 6.525 × 2 Gy RTThigh
30.528.5UPSHigh18.0 × 9.0 × 6.025 × 2 Gy RTUpper arm
41.030.9Malignant peripheral nerve
sheath tumor
Intermediate2.5 × 1.6 × 1.525 × 2 Gy RTUpper arm
51.026.9Myxoinflammatory
fibroblastic
sarcoma/hemosiderotic
fibrolipomatous tumor
Low31.0 × 20.0 × 1.3NoneLeg
61.026.5UPSHigh3.6 × 2.9 × 1.2NoneUpper arm
71.04.8Metastatic clear cell
sarcoma
High4.0 × 2.9 × 2.8NoneInguinal lymph node
81.07.2UPSHigh13.0 × 6.5 × 7.125 × 2 Gy RTUpper arm
91.08.3IDC: ER+/PR/Her2+High3.7NoneBreast
101.59.6IDC: ER+/PR+/Her2Intermediate7.5 × 2.5 ×1.5NoneBreast
111.55.1Metastatic spindle cell
sarcoma
Low0.9NoneThigh
121.57.3MyxofibrosarcomaHigh11.0 × 6.5 × 6.5NoneThigh
130.59.6Synovial sarcomaHigh20.0 × 12.0 × 6.025 × 2 Gy RTThigh
140.58.5Spindle cell sarcomaHigh7.525 × 2 Gy RTThigh
150.57.3IDC: ER+, PR+, Her2High2.4 × 1.6 × 1.4NoneBreast